Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).
Epistemonikos ID: 815f51afe3e9858fbda111b4aa3bc892c2df5085
First added on: Mar 23, 2020